Research and intellectual property involving human material: after all, from whom are our genes?
DOI:
https://doi.org/10.29397/reciis.v10i1.1046Keywords:
Patents, Genes, Intellectual property, Genetic research, Genes BRCA1, Genes BRCA2.Abstract
This article discusses ethical, scientific and legal aspects of the patenting of human genes, starting from a historical context of intellectual property of living beings and passing through the decision of the US Supreme Court in Myriad Genetics case, conflict over patent of the genes BRCA1 and BRCA2, related to breast cancer and ovarian cancer. Moreover, the article discusses regulatory instruments on the subject, considering both the Brazilian and international legislation. Finally, it contrasts different positions on patent of human genes, adopting critical position that this matter deserves.
Downloads
Published
How to Cite
Issue
Section
License
Author’s rights: The author retains unrestricted rights over his work.
Rights to reuse: Reciis adopts the Creative Commons License, CC BY-NC non-commercial attribution according to the Policy on Open Access to Knowledge by Oswaldo Cruz Foundation. With this license, access, download, copy, print, share, reuse, and distribution of articles is allowed, provided that it is for non-commercial use and with source citation, granting proper authorship credits and reference to Reciis. In such cases, no permission is required from the authors or editors.
Rights of authors’s deposit / self-archiving: The authors are encouraged to deposit the published version, along with the link of their article in Reciis, in institutional repositories.